Benzinga | Oct 29, 2020 07:44AM EDT

Blueprint Medicines Q3 EPS $11.16 Beats $7.72 Estimate, Sales $745.12M Beat $631.57M Estimate

Blueprint Medicines (NASDAQ:BPMC) reported quarterly earnings of $11.16 per share which beat the analyst consensus estimate of $7.72 by 44.56 percent. This is a 678.24 percent increase over losses of $(1.93) per share from the same period last year. The company reported quarterly sales of $745.12 million which beat the analyst consensus estimate of $631.57 million by 17.98 percent. This is a 8.05K percent increase over sales of $9.14 million the same period last year.